We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


bmd Enters two Diagnostic Markets with the Launch of FIDIS™ Kits

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute

bmd (BioMedical Diagnostics SA) has announced three kits in two diagnostic fields. These are infectious serology and genetic diseases.

Two of the kits are for the detection of the Epstein Barr virus (EBV), which causes infectious mononucleosis (glandular fever). The third kit tests for a patient's predisposition to cardiovascular disease.

"bmd continues to expand its range of FIDIS™ multiplex kits and now enters these two new application areas," said Dr Patrick G Poty, bmd CEO.

"Available to private medical laboratories as well as hospitals, the new products reinforce bmd's position as a major player in high throughput profiling."

"This move into new applications demonstrates the excellent outlook for bmd as we prepare our IPO in Paris on Alternext," added Poty.

The FIDIS™ EBV G and EBV M kits are designed to reveal the presence of G and M antibodies against the Epstein Barr virus, which causes infectious mononucleosis in immuno-depressed patients, transplant recipients and young persons.

Widespread testing for this disease is already carried out in Europe and the US. The kits are designed to provide medical laboratories with a rational solution to the problem and boost bmd's position as leader in this area, currently covered with ELISA or unitary tests.

Planned kits will address respiratory diseases, sexually transmissible diseases, vaccination follow-up and viral meningitis.

FIDIS™ Multiplex technology is a match for the diagnosis of genetic diseases. This has enabled bmd to launch its first test to detect predisposition to cardiovascular diseases.

The first application is Apoliprotein E (APO E). APO E is an essential vector of blood lipids, which are components of coronary plaque.

One of APO E's polymorphisms, APO E4, is an indicator of high risk of heart failure in 75 percent of cases when it is associated with a high level of LDL cholesterol (a type of lipoprotein).

Patients who carry allele APO E4 respond better to anti-cholesterol drugs and benefit more from dietary regimes.

bmd claims that, used in conjunction with FIDIS™, its Multiplex diagnostic system, these different kits allow the fast, accurate and distinct measurement of several antibodies or alleles after a one-hour incubation.